



Now Available Through
Purdue Pharma

**FOQUEST[®] methylphenidate hydrochloride
controlled release capsules**

Purdue Pharma would like to announce the launch of FOQUEST[®], a new product (methylphenidate hydrochloride controlled release capsules), indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults (≥18 years of age). FOQUEST[®] is now available.



Route of Administration	Dosage Form/Strength
Oral	Controlled Release Capsules: 25, 35, 45, 55, 70, 85 and 100 mg

Available to order through your wholesaler. For inquiries, please contact Customer Service by phone (toll free: 1-800-387-4501) or email (customerservice@purdue.ca).

Product Information							
Format	25 mg capsules	35 mg capsules	45 mg capsules	55 mg capsules	70 mg capsules	85 mg capsules	100 mg capsules
DIN	02470292	02470300	02470314	02470322	02470330	02470349	02470357
UPC	0 60025 42203 4	0 60025 42204 1	0 60025 42205 8	0 60025 42206 5	0 60025 42207 2	0 60025 42208 9	0 60025 42209 6
Purdue Product Code	42203	42204	42205	42206	42207	42208	42209

Consult the Product Monograph at <http://purdue.ca/en/products/Foquest-PM> for contraindications, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The Product Monograph is also available by calling 1-800-387-4501.



1. FOQUEST[®] Product Monograph, December 5, 2017.
FOQUEST[®] is a registered trademark of Purdue Pharma
575 Granite Court, Pickering, ON L1W 3W8 Canada
©2018 Purdue Pharma. All rights reserved.